Page 7 of 10
ACS Catalysis
Chem. Soc. 1981, 103, 2127-2129. (d) Evans, D. A. Studies in
Bioavailable and Brain Penetrant Mutant IDH1 Inhibitors. ACS Med.
Chem. Lett. 2018, 9, 746-751. (c) Lin, J.; Lu, W.; Caravella, J. A.;
Campbell, A. M.; Diebold, R. B.; Ericsson, A.; Fritzen, E.; Gustafson,
G. R.; Lancia, D. R.; Shelekhin, Jr. T.; Wang, Z.; Castro, J.; Clarke, A.;
Gotur, D.; Josephine, H. R.; Katz, M.; Diep, H.; Kershaw, M.; Yao, L.;
Kauffman, G.; Hubbs, S. E.; Luke, G. P.; Toms, A. V.; Wang, L.; Bair,
K. W.; Barr, K. J.; Dinsmore, C.; Walker, D.; Ashwell, S. Discovery
and Optimization of Quinolinone Derivatives as Potent, Selective, and
Orally Bioavailable Mutant Isocitrate Dehydrogenase 1 (mIDH1)
Inhibitors. J. Med. Chem. 2019, 62, 6575-6596.
asymmetric synthesis. The development of practical chiral enolate
synthons. Aldrichim. Acta. 1982, 15, 23-32. (e) Ager, D. J.; Prakash, I.;
Schaad, D. R. 1,2-Amino Alcohols and Their Heterocyclic Derivatives
as Chiral Auxiliaries in Asymmetric Synthesis. Chem. Rev. 1996, 96,
835-876. (f) Ager, D. J.; Prakash, I.; Schaad, D. R. Chiral
oxazolidinones in asymmetric synthesis. Aldrichim. Acta. 1997, 30, 3-
12. (g) Wu, Y.; Shen, X. A high-yielding low-cost facile synthesis of
2-oxazolidinones chiral auxiliaries. Tetrahedron: Asymmetry 2000, 11,
4359-4363. (h) Evans, D. A.; Gage, J. R.; Leighton, J. L. Total
Synthesis of (+)-Calyculin A. J. Am. Chem. Soc. 1992, 114, 9434-9453.
(i) Zappia, G.; Gacs-Baitz, E.; Monache, G. D.; Misiti, D.; Nevola, L.;
Botta, B. Oxazolidin-2-one Ring, a Popular Framework in Synthetic
Organic Chemistry: Part 1. The Construction of the Oxazolidin-2-one
Ring. Curr. Org. Synth. 2007, 4, 81-135. (j) Zappia, G.; Cancelliere,
G.; Gacs-Baitz, E.; Delle Monache, G.; Misiti, D.; Nevola, L.; Botta,
B. Oxazolidin-2-one Ring, a Popular Framework in Synthetic Organic
Chemistry Part 2 [1]. Applications and Modifications. Curr. Org. Synth.
2007, 4, 238-307.
(2) For some selected examples: (a) Dyen, M. E.; Swern, D. 2-
OXAZOLIDONES. Chem. Rev. 1967, 67, 197-246. (b) Gregory, W.
A.; Brittelli, D. R.; Wang, C.-L.; Wuonola, M. A.; McRipley, R. J.;
Eustice, D. C.; Eberly, V. S.; Bartholomew, P. T.; Slee, A. M.; Forbes,
M. Antibacterials. Synthesis and Structure-Activity Studies of 3-Aryl-
2-oxooxazolidines. 1. The "B" Group. J. Med. Chem. 1989, 32, 1673-
1681. (c) Grega, K. C.; Barbachyn, M. R.; Brickner, S. J.; Mizsak, S.
A. Regioselective Metalation of Fluoroanilines. An Application to the
Synthesis of Fluorinated Oxazolidinone Antibacterial Agents. J. Org.
Chem. 1995, 60, 5255-5261. (d) Brickner, S. J.; Hutchinson, D. K.;
Barbachyn, M. R.; Manninen, P. R.; Ulanowicz, D. A.; Garmon, S. A.;
Grega, K. C.; Hendges, S. K.; Toops, D. S.; Ford, C. W.; Zurenko, G.
E. Synthesis and Antibacterial Activity of U-100592 and U-100766,
Two Oxazolidinone Antibacterial Agents for the Potential Treatment
of Multidrug-Resistant Gram-Positive Bacterial Infections. J. Med.
Chem. 1996, 39, 673-679. (e) Wang, G.; Hollingsworth, R. I. A simple
three-step method for preparing homochiral 5-trityloxymethyl-2-
1
2
3
4
5
6
7
8
(4) (a) Kakeya, H.; Morishita, M.; Kobinata, K.; Osono, M.; Ishizuka,
M.; Osada, H. Isolation and Biological Activity of a Novel Cytokine
Modulator, Cytoxazone. J. Antibiot. 1998, 51, 1126-1128. (b) Kakeya,
H.; Morishita, M.; Koshino, H.; Morita, T.-i.; Kobayashi, K.; Osada, H.
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Cytoxazone:
A Novel Cytokine Modulator Containing a 2-
Oxazolidinone Ring Produced by Streptomyces sp. J. Org. Chem. 1999,
64, 1052-1053. (c) Sakamoto, Y.; Shiraishi, A.; Seonhee, J.; Nakata, T.
Stereoselective syntheses of cytoxazone, a novel cytokine modulator,
and its stereoisomers. Tetrahedron Lett. 1999, 40, 4203-4206.
(5) (a) Johnson, D. E.; Rollema, H.; Schmidt, A. W.; McHarg, A. D.
Serotonergic effects and extracellular brain levels of eletriptan,
zolmitriptan and sumatriptan in rat brain. Eur. J. Pharmacol. 2001, 425,
203-210. (b) Goadsby, P.; Hoskin, K. Inhibition of trigeminal neurons
by intravenous administration of the serotonin (5HT)1B/D receptor
agonist zolmitriptan (311C90): are brain stem sites therapeutic target in
migraine? Pain, 1996, 67, 355-359. (c) Martin, G. R.; Robertson, A.
D.; MacLennan, S. J.; Prentice, D. J.; Barrett, V. J.; Buckingham, J.;
Honey, A. C.; Giles, H.; Moncada, S. Receptor specificity and
trigemino-vascular inhibitory actions of a novel 5-HT1B/1D receptor
partial agonist, 311C90 (zolmitriptan). Brit. J. Pharmacol. 1997, 121,
157-164.
(6) For some selected examples: (a) Tadao, I.; Koreichi, K.; Seigo,
I.; Takehisa, K. Practical Preparation of Chiral 4-Substituted 2-
Oxazolidinones. Chemistry Lett. 1992, 21, 991-994. (b) Lewis, N.;
McKillop, A.; Taylor, R. J. K.; Watson, R. J. A Simple and Efficient
Procedure for the Preparation of Chiral 2-Oxazolidinones from α-
Amino Acids. Synth. Commun. 1995, 25, 561-568. (c) Neri, C.;
Williams, J. M. J. New Routes to Chiral Evans Auxiliaries by
Enzymatic Desymmetrisation and Resolution Strategies. Adv. Synth.
Catal. 2003, 345, 835-848. (d) Madhusudhan, G.; Reddy, G. O.; Rajesh,
T.; Ramanatham, J.; Dubey, P. K. Stereoselective synthesis of novel
(R)- and (S)-5-azidomethyl 2-oxazolidinones from (S)-
epichlorohydrin: a key precursor for the oxazolidinone class of
antibacterial agents. Tetrahedron Lett. 2008, 49, 3060-3062.
(7) (a) Ben-Ishai, D. The Reactions of β-Hydroxyethylamides and β-
Hydroxyethylcarbamates with Phosgene. J. Am. Chem. Soc. 1956, 78,
4962-4965. (b) Pridgen, L. N.; Prol, J.; Alexander, B.; Gillyard, L.
Single-Pot Reductive Conversion of Amino Acids to Their Respective
2-Oxazolidinones Employing Trichloromethyl Chloroformate as the
Acylating Agent: A Multigram Synthesis. J. Org. Chem. 1989, 54,
3231-3233. (c) Sibi, M. P.; Renhowe, P. A. A new nucleophilic alaninol
synthon from serine. Tetrahedron Lett. 1990, 31, 7407-7410. (d)
Gabriele, B.; Salerno, G.; Brindisi, D.; Costa, M.; Chiusoli, G. P.
Synthesis of 2-Oxazolidinones by Direct Palladium-Catalyzed
Oxidative Carbonylation of 2-Amino-1-alkanols. Org. Lett. 2000, 2,
625-627. (e) Li, P.; Yuan, X.; Wang, S.; Lu, S. A novel way to chiral
2-oxazolidinones: selenium-catalyzed cyclocarbonylation of 2-
aminoethanols. Tetrahedron, 2007, 63, 12419-12423. (f) Paz, J.; Pérez-
Balado, C.; Iglesias, B.; Muñoz, L. Carbon Dioxide as a Carbonylating
Agent in the Synthesis of 2-Oxazolidinones, 2-Oxazinones, and Cyclic
Ureas: Scope and Limitations. J. Org. Chem. 2010, 75, 3037-3046. (g)
Pulla, S.; Felton, C. M.; Gartia, Y.; Ramidi, P.; Ghosh, A. Synthesis of
2‑ Oxazolidinones by Direct Condensation of 2‑ Aminoalcohols with
Carbon Dioxide Using Chlorostannoxanes. ACS Sustainable Chem.
Eng. 2013, 1, 309-312. (h) Wu, X.-F.; Neumann, H.; Beller, M.
Synthesis of Heterocycles via Palladium-Catalyzed Carbonylations.
Chem. Rev. 2013, 113, 1-35.
oxazolidinones
from
optically
active
3-hydroxy-g-
butyrolactones.Tetrahedron: Asymmetry 2000, 11, 4429-4432. (f)
Gravestock, M. B.; Acton, D. G.; Betts, M. J.; Dennis, M.; Hatter, G.;
McGregor, A.; Swain, M. L.; Wilson, R. G.; Woods, L.; Wookey, A.
New Classes of Antibacterial Oxazolidinones with C-5, Methylene O-
Linked Heterocyclic Side Chains. Bioorg. Med. Chem. Lett. 2003, 13,
4179-4186. (g) Mukhtar, T. A.; Wright, G. D. Streptogramins,
Oxazolidinones, and Other Inhibitors of Bacterial Protein Synthesis.
Chem. Rev. 2005, 105, 529-542. (h) Renslo, A. R.; Luehr, G. W.;
Gordeev, M. F. Recent developments in the identification of novel
oxazolidinone antibacterial agents. Bioorg. Med. Chem. 2006, 14,
4227-4240. (i) Zappia, G.; Menendez, P.; Delle Monache, G.; Misiti,
D.; Nevola, L.; Botta, B. The Contribution of Oxazolidinone Frame to
The Biological Activity of Pharmaceutical Drugs and Natural Products.
Mini-Rev. Med. Chem. 2007, 7, 389-409. (j) Renslo, A. R. Antibacterial
oxazolidinones: emerging structure–toxicity relationships. Expert Rev.
Anti-infect. 2010, 8, 565-574. (k) Jadhavar, P. S.; Vaja, M. D.;
Dhameliya, T. M.; Chakraborti, A. K. Oxazolidinones as Anti-
tubercular Agents: Discovery, Development and Future Perspectives.
Curr. Med. Chem. 2015, 22, 4379-4397.
(3) (a) Levell, J. R.; Caferro, T.; Chenail, G.; Dix, I.; Dooley, J.;
Firestone, B.; Fortin, P. D.; Giraldes, J.; Gould, T.; Growney, J. D.;
Jones, M. D.; Kulathila, R.; Lin, F.; Liu, G.; Mueller, A.; van der Plas,
S.; Slocum, K.; Smith, T.; Terranova, R.; Touré, B. B.; Tyagi, V.;
Wagner, T.; Xie, X.; Xu, M.; Yang, F. S.; Zhou, L. X.; Pagliarini, R.;
Cho, Y. S. Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as
Allosteric and Mutant Specific Inhibitors of IDH1. ACS Med. Chem.
Lett. 2017, 8, 151-156. (b) Zhao, Q.; Manning, J. R.; Sutton, J.;
Costales, A.; Sendzik, M.; Shafer, C. M.; Levell, J. R.; Liu, G.; Caferro,
T.; Cho, Y. S.; Palermo, M.; Chenail, G.; Dooley, J.; Villalba, B.;
Farsidjani, A.; Chen, J.; Dodd, S.; Gould,T.; Liang, G.; Slocum, K.; Pu,
M.; Firestone, B.; Growney, J.; Heimbach, T.; Pagliarini, R.
Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Orally
(8) (a) Jung, M. E.; Jung, Y. H. Rapid synthesis of β-hydroxy-α-
amino acids, such as L-threonine, β-hydroxyphenylalanine, and β-
ACS Paragon Plus Environment